Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension

被引:4
作者
Ruilope, LM [1 ]
Segura, J [1 ]
机构
[1] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
关键词
cardiovascular disease; hypertension; risk assessment;
D O I
10.1016/j.clinthera.2005.10.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Accurate assessment of cardiovascular disease (CVD) risk in patients with hypertension is important when planning appropriate treatment of modifiable risk factors. The causes of CVD are multifactorial, and hypertension seldom exists as an isolated risk factor. Classic models of risk assessment are more accurate than a simple counting of risk factors, but they are not generalizable to all populations. In addition, the risk associated with hypertension is graded, continuous, and independent of other risk factors, and this is not reflected in classic models of risk assessment. Objective: This article is intended to review both classic and newer models of CVD risk assessment. Methods: MEDLINE was searched for articles published between 1990 and 2005 that contained the terms cardiovascular disease, hypertension, or risk assessment. Articles describing major clinical trials, new data about cardiovascular risk, or global risk stratification were selected for review. Results: Some patients at high long-term risk for CVD events (eg, patients aged <50 years with multiple risk factors) may go untreated because they do not meet the absolute risk-intervention threshold of 20% risk over 10 years with the classic model. Recognition of the limitations of classic risk-assessment models led to new guidelines, particularly those of the European Society of Hypertension-European Society of Cardiology. These guidelines view hypertension as one of many risk and disease factors that require treatment to decrease risk. These newer guidelines include a more comprehensive range of risk factors and more finely graded blood pressure ranges to stratify patients by degree of risk. Whether they accurately predict CVD risk in most populations is not known. Evidence from the Valsartan Ant1hypertensive Long-term Use Evaluation (VALUE) study, which stratified patients by several risk and disease factors, highlights the predictive value of some newer CVD risk assessments. Conclusion: Modern risk assessments, which include blood pressure along with a wide array of modifiable risk factors, may be more accurate than classic models for CVD risk prediction.
引用
收藏
页码:1658 / 1668
页数:11
相关论文
共 50 条
  • [1] Hypertension guidelines: Criteria that might make them more clinically useful
    Alderman, MH
    Furberg, CD
    Kostis, JB
    Laragh, JH
    Psaty, BM
    Ruilope, LM
    Volpe, M
    Jackson, R
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (10) : 917 - 923
  • [2] *AM HEART ASS, 2004, 2005 HEART STROK STA
  • [3] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS
    ANDERSON, KM
    WILSON, PWF
    ODELL, PM
    KANNEL, WB
    [J]. CIRCULATION, 1991, 83 (01) : 356 - 362
  • [4] [Anonymous], 1990, Circulation, V82, P1616
  • [5] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
  • [6] The Framingham prediction rule is not valid in a European population of treated hypertensive patients
    Bastuji-Garin, S
    Deverly, A
    Moyse, D
    Castaigne, A
    Mancia, G
    de Leeuw, PW
    Ruilope, LM
    Rosenthal, T
    Chatellier, G
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (10) : 1973 - 1980
  • [7] Chalmers J, 1999, J HYPERTENS, V17, P151
  • [8] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project
    Conroy, RM
    Pyörälä, K
    Fitzgerald, AP
    Sans, S
    Menotti, A
    De Backer, G
    De Bacquer, D
    Ducimetière, P
    Jousilahti, P
    Keil, U
    Njolstad, I
    Oganov, RG
    Thomsen, T
    Tunstall-Pedoe, H
    Tverdal, A
    Wedel, H
    Whincup, P
    Wilhelmsen, L
    Graham, IM
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (11) : 987 - 1003